ArticleOncotarget2017
Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mitochondrial Adaptations Underlying Tetraploidization in Human Cancer, Fungal, and Yeast Models.Biology · 2026Article
- Yeast with elevated chromosome numbers are addicted to high levels of Mps1.bioRxiv : the preprint server for biology · 2025Article
- Tetraploidization Increases the Motility and Invasiveness of Cancer Cells.International journal of molecular sciences · 2023Article
- Complex Interplay of Genes Underlies Invasiveness in Fibrosarcoma Progression Model.Journal of clinical medicine · 2021Article
- The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.NPJ breast cancer · 2021Article
- Article
- Inhibition of mitotic kinase Mps1 promotes cell death in neuroblastoma.Scientific reports · 2020Article
- Genome remodeling upon mesenchymal tumor cell fusion contributes to tumor progression and metastatic spread.Oncogene · 2020Article
- Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1.Scientific reports · 2018Article
- The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas with complex genomics are very heterogeneous tumors lacking simple prognosis markers or targeted therapies. Overexpression of a subset of mitotic genes from a signature called CINSARC is of bad prognosis, but the significance of this signature remains elusive. Here we precisely measure the cell cycle and mitosis duration of sarcoma cell lines and we found that the mitotic gene products overexpression does not reflect variation in the time spent during mitosis or G2/M. We also found that the CINSARC cell lines, we studied, are composed of a mixture of aneuploid, diploid, and tetraploid cells that are highly motile in vitro. After sorting diploid and tetraploid cells, we showed that the tetraploid cell clones do not possess a proliferative advantage, but are strikingly more motile and invasive than their diploid counterparts. This is correlated with higher levels of mitotic proteins overexpression. Owing that mitotic proteins are almost systematically degraded at the end of mitosis, we propose that it is the abnormal activity of the mitotic proteins during interphase that boosts the sarcoma cells migratory properties by affecting their cytoskeleton. To test this hypothesis, we designed a screen for mitotic or cytoskeleton protein inhibitors affecting the sarcoma cell migration potential independently of cytotoxic activities. We found that inhibition of several mitotic kinases drastically impairs the CINSARC cell invasive and migratory properties. This finding could provide a handle by which to selectively inhibit the most invasive cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.